Social differences in lung cancer management and survival in South East England: a cohort study. by Berglund, Anders et al.
Berglund, A; Lambe, M; Lchtenborg, M; Linklater, K; Peake, MD;
Holmberg, L; Mller, H (2012) Social differences in lung cancer man-
agement and survival in South East England: a cohort study. BMJ
Open, 2 (3). ISSN 2044-6055
Downloaded from: http://researchonline.lshtm.ac.uk/24957/
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Creative Commons Attribution Non-commercial No Derivatives
http://creativecommons.org/licenses/by-nc-nd/2.5/
Social differences in lung cancer
management and survival in South East
England: a cohort study
Anders Berglund,1,2 Mats Lambe,1,2 Margreet Lu¨chtenborg,3 Karen Linklater,3
Michael D Peake,4,5 Lars Holmberg,2,3 Henrik Møller3
ABSTRACT
Objective: To examine possible social variations in
lung cancer survival and assess if any such gradients
can be attributed to social differences in comorbidity,
stage at diagnosis or treatment.
Design: Population-based cohort identified in the
Thames Cancer Registry.
Setting: South East England.
Participants: 15 582 lung cancer patients diagnosed
between 2006 and 2008.
Main outcome measures: Stage at diagnosis,
surgery, radiotherapy, chemotherapy and survival.
Results: The likelihood of being diagnosed as having
early-stage disease did not vary by socioeconomic
quintiles (p¼0.58). In early-stage non-small-cell lung
cancer, the likelihood of undergoing surgery was
lowest in the most deprived group. There were no
socioeconomic differences in the likelihood of
receiving radiotherapy in stage III disease, while in
advanced disease and in small-cell lung cancer, receipt
of chemotherapy differed over socioeconomic quintiles
(p<0.01). In early-stage disease and following
adjustment for confounders, the HR between the most
deprived and the most affluent group was 1.24 (95%
CI 0.98 to 1.56). Corresponding estimates in stage III
and advanced disease or small-cell lung cancer were
1.16 (95% CI 1.01 to 1.34) and 1.12 (95% CI 1.05 to
1.20), respectively. In early-stage disease, the crude
HR between the most deprived and the most affluent
group was approximately 1.4 and constant through
follow-up, while in patients with advanced disease or
small-cell lung cancer, no difference was detectable
after 3 months.
Conclusion: We observed socioeconomic variations in
management and survival in patients diagnosed as
having lung cancer in South East England between
2006 and 2008, differences which could not fully be
explained by social differences in stage at diagnosis,
co-morbidity and treatment. The survival observed in
the most affluent group should set the target for what
is achievable for all lung cancer patients, managed in
the same healthcare system.
The overall prognosis of lung cancer is
particularly poor in the UK with recent esti-
mates showing a 5-year relative survival of
6.5% and 8.4% for men and women,
respectively.1 Observed national differences
appear to be most pronounced early in the
period of follow-up.1 2 Outcome in early-
stage lung cancer is highly dependent on
management, where pulmonary resection
offers a potentially curative treatment
modality.3 4 Approximately 10% of all lung
cancer patients in the UK underwent surgical
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ARTICLE SUMMARY
Article focus
- Social differences in management and survival in
lung cancer patients.
- Particular focus on possible social variations in
lung cancer survival and assess if any such
gradients can be attributed to social differences
in co-morbidity, stage at diagnosis or treatment.
Key messages
- There were no detectable socioeconomic differ-
ences in stage at diagnosis among lung cancer
patients in South East England between 2006 and
2008.
- Socioeconomic differences in lung cancer
management and survival existed. The observed
inequalities in survival could not fully be
explained by social differences in stage at
diagnosis, co-morbidity and treatment factors.
- In early-stage disease, social gradients in
survival existed throughout follow-up, whereas
in advanced disease, variations in survival
were confined to the period immediately after
diagnosis.
Strengths and limitations of this study
- Strengths included the population-based cohort
design. The material at hand allowed analyses
that accounted for co-morbidity, stage at diag-
nosis and treatment factors.
- Limitations included the absence of data on
performance status, forced expiratory volume,
smoking history and lifestyle factors.
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resection between 2004 and 2006,5 which is lower than
corresponding estimates in some other European
countries and the USA.6 7 Previous studies have found
evidence of both regional variations in treatment inten-
sity and socioeconomic inequalities in lung cancer
survival in the UK.8e12 While one important aim of the
National Health Service Cancer Plan in 2000 was to
reduce social inequalities in cancer survival,13 marked
differences persisted 10 years later.14 Several factors may
contribute to social gradients in cancer survival
including the patient’s general health status, knowledge
and healthcare seeking behaviours, characteristics of the
tumour at time of diagnosis and clinical management.
Differences in the management of patients in relation to
socioeconomic factors, including the use of surgery in
non-small-cell lung cancer patients, have previously been
reported in the UK and in other countries.15 16 The
present study was based on patients diagnosed as having
lung cancer identified in the Thames Cancer Registry
between 2006 and 2008 and aimed to examine possible
social gradients in lung cancer survival and assess if any
such variation can be attributed to social differences in
co-morbidity, stage at diagnosis and treatment.
METHODS
Data collection
The Thames Cancer Registry is population based and
currently covers a population of 12 million people in
South East England (London, Kent, Surrey and Sussex).
The Thames Cancer Registry registers approximately
57 000 incident cancer cases annually. Cancer registra-
tion is based on clinical and pathological information
received from hospitals and from death certificates
provided by the Office for National Statistics. Hospital
episode statistics data are obtained from hospital patient
administration systems and include information on the
patient, as well as clinical and administrative details. The
UK National Lung Cancer Audit was set up in 2004 as
a clinical database for all new lung cancer patients. The
number of trusts participating in this audit increased
from 40% in 2005 to 85% in England and Wales in
2008.17 While information on items such as stage at
diagnosis and treatment details are incompletely
recorded in the cancer registry data set, these can be
supplemented by means of record linkage to the
National Lung Cancer Audit and hospital episode
statistics.18 The large majority of the relevant healthcare
providers in South East England are part of a national
tax-funded health system, with only a minority of lung
cancer patients being managed by private providers.
For the purpose of the present study, we identified
lung cancer cases registered with International Classifi-
cation of Diseases-10th Revision codes C33 and C34 from
the Thames Cancer Registry database. Data on surgery
and radiotherapy were retrieved from hospital episode
statistics and supplemented with data from Thames
Cancer Registry, while information on stage and
chemotherapy was obtained from the Cancer Registry
and supplemented with data from the National Lung
Cancer Audit. Information on stage at diagnosis was
available for 72.7% of the patients. The definition of
primary initial treatment (surgical resection, radio-
therapy and chemotherapy) was based on simple binary
indicators. No treatment and no record of treatment
cannot be distinguished in these data.
Study population
A total of 16 183 patients with a diagnosis of lung cancer
between 2006 and 2008 were identified in the Thames
Cancer Registry. Following exclusion of death certificate-
only cancer registrations (601 cases or 3.7% of the total),
the final study population consisted of 15 582 cases.
Patients were subdivided into three subgroups according
to disease status: early-stage (stages IAeIIB) non-small-
cell lung cancer (n¼1828), stage III non-small or small-
cell lung cancer (n¼2771) and advanced stage (stages
IIIAeIV) disease or all stages of small-cell lung cancer
(n¼10 039). These three groups were created on the
basis of the most commonly used initial treatment
modalities in every subgroup.
Co-morbidity
A modified version of the Charlson comorbidity index
was used to assess the burden of concomitant disease for
each patient, following retrieval of information on co-
morbidity from the hospital episode statistics in a 3-year
period preceding the lung cancer diagnosis. The orig-
inal Charlson comorbidity index consists of 19 disease
groups and has been used in earlier studies that have
assessed the role of concomitant disease in cancer
patients.19e21 In the present study, all groups except
cancer were included. Each disease group was then
assigned a specific weight (1, 2, 3 and 6) depending on
the severity of the medical condition. The Charlson
index was derived by summing the weighted scores for
all comorbidities. On the basis of the distribution of the
Charlson score, the patients were classified into three co-
morbidity categories: no (0), mild (1) and severe co-
morbidity (2+). Information was available for 88.4% of
the patients. For 1808 patients, no link to the hospital
episode statistics data could be established.
Socioeconomic quintile
Socioeconomic status recorded in the Thames Cancer
Registry is based on the income domain of the 2007
Indices of Deprivation22 in which patients are classified
based on their postcode of residence and are categorised
into quintiles of socioeconomic deprivation. The most
affluent group was labelled Q1 and the most deprived Q5.
Statistical methods
Among all patients, crude and adjusted binary logistic
regression models with ORs and 95% CIs were used for
prediction of the probability of being diagnosed as having
early-stage disease by socioeconomic quintile. In a subse-
quent step, the likelihood to undergo surgical resection
(in early-stage non-small-cell lung cancer) to receive
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radiotherapy (in stage III disease) and to receive
chemotherapy (in advanced disease or small-cell lung
cancer) were assessed by using crude and adjusted binary
logistic regression models. All models were adjusted for
sex, age at diagnosis and the Charlson comorbidity index.
In time to event analysis, the outcome of interest was
all-cause mortality. Survival time was defined as the
interval between the date of the lung cancer diagnosis
and the date of death, emigration or end of follow-up on
31 December 2009. For each clinical subgroup (early-
stage non-small-cell lung cancer, stage III disease and
advanced stage or small-cell lung cancer), Cox regres-
sion models were used to calculate HRs and 95% CIs for
all-cause mortality in relation to socioeconomic quin-
tiles. Both univariate and multivariate models adjusted
for sex, age at diagnosis, co-morbidity and treatment
factors were used. We used multiple imputation to
account for missing information on co-morbidity using
chained equations with 60 imputated data sets.23
The relative contribution (%) of adding each covariate
separately in explaining the possible social variation in
mortality between the most affluent and the most
deprived patients in each subgroup was calculated as
follows: ((HR for SESQ5 in model A  HR for SESQ5 in
model B)/(HR for SESQ5 in model A  1))3100, where
model A is the basic model (socioeconomic quintiles
and adjusted for sex) and in model B, with each cova-
riate being added to model A.
Cumulative survival and mortality rates (per 100 person-
years) were estimated by subgroups and socioeconomic
quintile. The mortality rates were calculated as number of
deaths divided by the person-years at risk. These estimates
were modelled with flexible parametric survival models
using a restricted cubic spline for the baseline mortality
rate.24 These models, similar to Cox regression models,
provide HRs as measures of association between expo-
sures and outcome. By modelling the underlying rate
parametrically, it is possible to estimate fitted curves from
the model, such as the cumulative survival function. In
the Cox regression models, we estimated a single HR
between socioeconomic quintiles, assumed to be constant
throughout follow-up. In the flexible parametric survival
framework, the HR between the most deprived versus
most affluent patients was estimated in predefined
segments of the follow-up, using a second spline function.
The HR is then time dependent on the underlying
timescale that was time since diagnosis of lung cancer. All
flexible parametric survival models were estimated using
the stpm2-package in STATA.25
In all analyses, we computed c2 tests and p values for
trend by fitting a linear categorical variable. All p values
are two sided, and statistical significance was considered
at p<0.05. The statistical analyses were performed using
STATA V.11, and graphical displays were produced using
R V. 10.2.26
RESULTS
Demographic and clinical characteristics
Table 1 shows the demographic and clinical character-
istics by socioeconomic quintile. The most affluent
Table 2 The likelihood of being diagnosed as having early-stage disease* estimated by crude and adjusted regression models
with ORs and 95% CIs
N (%)
Crude Adjusted
OR 95% CI OR 95% CI
Socioeconomic quintile
Q1 (affluent) 236 (15.4) 1.00 Reference 1.00 Reference
Q2 341 (18.6) 1.25 1.04 to 1.50 1.24 1.04 to 1.49
Q3 369 (16.9) 1.12 0.93 to 1.34 1.11 0.93 to 1.33
Q4 492 (17.9) 1.20 1.01 to 1.42 1.18 1.00 to 1.40
Q5 (deprived) 480 (15.8) 1.03 0.87 to 1.22 1.01 0.85 to 1.20
Test for trend (c2, p value) 0.18 0.67 0.59 0.44
Sex
Male 1037 (15.9) 1.00 Reference 1.00 Reference
Female 881 (18.3) 1.19 1.08 to 1.30 1.10 1.10 to 1.33
Test for trend (c2, p value) 11.5 <0.01 12.6 <0.01
Age at diagnosis
0e59 300 (15.2) 1.00 Reference 1.00 Reference
60e69 550 (17.6) 1.19 1.02 to 1.39 1.16 0.99 to 1.35
70e79 694 (18.4) 1.26 1.08 to 1.46 1.18 1.01 to 1.37
80+ 374 (15.3) 1.01 0.85 to 1.19 0.93 0.78 to 1.10
Test for trend (c2, p value) 2.75 0.10 0.29 0.59
Charlson Score
0 719 (15.0) 1.00 Reference 1.00 Reference
1 511 (17.6) 1.19 1.05 to 1.34 1.19 1.05 to 1.34
2+ 504 (19.0) 1.29 1.14 to 1.47 1.31 1.15 to 1.49
Test for trend (c2, p value) 20.0 <0.01 21.7 <0.01
*The binary outcome was categorised into early-stage disease (stages IAeIIB at diagnosis) or advanced disease (stages IIIAeIV at diagnosis).
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Social differences in lung cancer management survival
patients were generally older than the most deprived
patients (p<0.01). The proportion of patients with
severe co-morbidity was higher in people categorised as
deprived (29.6%) in Q5 than in people belonging to the
affluent (23.8%) in Q1 (p<0.01). Among patients with
classifiable disease, the proportion of non-small-cell lung
cancer was higher in the most affluent group. No
statistically significant trend over the socioeconomic
quintiles was observed with regard to the likelihood to be
diagnosed as having early-stage disease (p¼0.44) (table
2). However, patients with co-morbidity were more likely
to be diagnosed as having early-stage disease (p<0.01).
Treatment modality
About half of patients (49.2%) with early-stage non-
small-cell lung cancer underwent surgical resection.
Surgery decreased from 55.8% in the most affluent
group to 46.9% in the most deprived group (p¼0.29)
(table 3). There was a significant reduction in surgical
resection with increasing age at diagnosis (trend p<0.01),
but not in relation to co-morbidity (trend p¼0.21), once
other variables were adjusted for. In patients with stage III
disease, 1054 (38.0%) had radiotherapy treatment
recorded (table 3). In this subgroup, there was no asso-
ciation between socioeconomic quintile and receipt of
radiotherapy (p¼0.67). In 10 039 patients registered with
advanced disease or small-cell lung cancer, 36.5% had
a record of chemotherapy (table 3). A statistically signif-
icant trend of reduced odds to receive chemotherapy was
observed with increasing levels of socioeconomic depri-
vation (p<0.01) and with increased age at diagnosis
(p<0.01) and co-morbidity burden (p<0.01).
Survival
Figure 1 shows estimated cumulative survival functions
by socioeconomic quintile generated by flexible para-
metric models. In patients with early-stage non-small-cell
lung cancer, the 3-year survival in the most affluent and
the most deprived group was 50% and 39%, respectively.
While survival in stage III disease and in advanced
disease or small-cell lung cancer was poor in all socio-
economic quintiles, the prognosis was somewhat better
in the most affluent group.
Table 4 shows the risk of all-cause mortality in patients
with early-stage non-small-cell lung cancer, in stage III
disease and advanced disease or small-cell lung cancer.
In early-stage non-small-cell lung cancer, the HR
between the most deprived versus most affluent group
was 1.24 (95% CI 0.98 to 1.56) following adjustment for
potential confounders. The corresponding estimates in
stage III disease and advanced disease or small-cell lung
cancer was 1.16 (95% CI 1.01 to 1.34) and 1.12 (95% CI
1.05 to 1.20), respectively. In none of the three clinical
subgroups, no independent statistically significant trend
by socioeconomic quintiles could be detected.
The relative contribution of age at diagnosis
explaining the social inequality in survival between the
most affluent and the most deprived patients was 34.6%
in stage III disease and 13.9% in advanced disease or
T
a
b
le
3
C
o
n
ti
n
u
e
d S
u
rg
ic
a
l
re
s
e
c
ti
o
n
in
e
a
rl
y
-s
ta
g
e
N
S
C
L
C
(N
[
1
8
2
8
)
R
a
d
io
th
e
ra
p
y
in
s
ta
g
e
II
I
d
is
e
a
s
e
(N
[
2
7
7
1
)
C
h
e
m
o
th
e
ra
p
y
in
a
d
v
a
n
c
e
d
o
r
S
C
L
C
(N
[
1
0
0
3
9
)
N
(%
)
C
ru
d
e
A
d
ju
s
te
d
N
(%
)
C
ru
d
e
A
d
ju
s
te
d
N
(%
)
C
ru
d
e
A
d
ju
s
te
d
O
R
9
5
%
C
I
O
R
9
5
%
C
I
O
R
9
5
%
C
I
O
R
9
5
%
C
I
O
R
9
5
%
C
I
O
R
9
5
%
C
I
C
h
a
rl
s
o
n
S
c
o
re
0
3
9
8
(5
8
.4
)
1
.0
0
R
e
fe
re
n
c
e
1
.0
0
R
e
fe
re
n
c
e
4
6
6
(4
1
.5
)
1
.0
0
R
e
fe
re
n
c
e
1
.0
0
R
e
fe
re
n
c
e
1
9
6
0
(4
5
.1
)
1
.0
0
R
e
fe
re
n
c
e
1
.0
0
R
e
fe
re
n
c
e
1
2
5
7
(5
2
.8
)
0
.8
2
0
.6
5
to
1
.0
3
0
.8
7
0
.6
8
to
1
.1
2
2
8
8
(3
9
.0
)
0
.9
0
0
.7
5
to
1
.0
9
0
.9
3
0
.7
6
to
1
.1
2
9
4
3
(3
7
.0
)
0
.7
2
0
.6
5
to
0
.7
9
0
.8
2
0
.7
4
to
0
.9
2
2
+
2
1
5
(4
4
.8
)
0
.6
0
0
.4
8
to
0
.7
6
0
.7
8
0
.6
0
to
1
.0
1
2
1
6
(3
2
.7
)
0
.7
0
0
.5
7
to
0
.8
5
0
.7
5
0
.6
1
to
0
.9
2
6
1
6
(2
6
.9
)
0
.4
6
0
.4
1
to
0
.5
1
0
.6
1
0
.5
4
to
0
.6
8
T
e
s
t
fo
r
tr
e
n
d
(c
2
,
p
v
a
lu
e
)
5
.1
2
<
0
.0
1
1
.5
7
0
.2
1
1
2
.9
<
0
.0
1
8
.2
0
<
0
.0
1
2
1
7
.1
<
0
.0
1
7
4
.3
<
0
.0
1
6 Berglund A, Lambe M, Lu¨chtenborg M, et al. BMJ Open 2012;2:e001048. doi:10.1136/bmjopen-2012-001048
Social differences in lung cancer management survival
small-cell lung cancer (table 4). The corresponding
percentages of co-morbidity burden explaining the
social inequality between the most affluent and the most
deprived patients was 17.4% in stage III disease and
11.0% in advanced disease or small-cell lung cancer.
Resection explained 42.3% in early-stage disease and
chemotherapy explained 23.4% in advanced disease or
small-cell lung cancer of the social variation in survival.
Figure 2 illustrates the variation in overall mortality
rates by time since diagnosis in the five socioeconomic
quintiles and the variation of HRs between the most
deprived and the most affluent group. In early-stage
non-small-cell lung cancer, socioeconomic variations in
the mortality rates were most pronounced in the first
months after diagnosis, but the differences persisted
12 months after diagnosis. A HR of approximately 1.4
between the most deprived and the most affluent group
remained constant during the follow-up.
In stage III disease, and in advanced disease or small-
cell lung cancer, the mortality rates peaked and varied by
socioeconomic quintiles primarily during the first
month postdiagnosis, but after 12 months, only a minor
social difference was observed. The same pattern was
observed in the time-dependent HR between the most
deprived and the most affluent group.
DISCUSSION
Main findings
Our study clearly demonstrates the presence of social
differences in management, and in survival in patients
diagnosed as having lung cancer in South East England
between 2006 and 2008, and observed social differences
could not fully be explained by differences in stage at
diagnosis, co-morbidity and treatment factors. In early-
stage disease, the social gradients existed throughout the
follow-up, whereas in advanced disease variations in
survival were confined to the period immediately after
diagnosis.
Methodological strengths and limitations
Strengths of our study included the population-based
approach where the analyses were based on a cohort that
included virtually all lung cancer patients diagnosed and
managed in South East England between 2006 and 2008.
For the purpose of the present study, additional infor-
mation was obtained from other sources than the
Thames Cancer Registry, including information on stage
at diagnosis and co-morbidity. A weakness was the
absence of stage at diagnosis for one-fourth of the
patients, which varied from 25.4% (Q5) to 27.9% (Q1)
by socioeconomic quintiles. Patients with missing infor-
mation on stage at diagnosis had particularly poor
prognosis, which indicates that they often had advanced
disease. Co-morbidity burden was assessed by using the
Charlson comorbidity index that previously has been
shown to be associated with the management of and
outcomes in cancer patients,20 including lung cancer.27
However, since no information was available on medical
conditions not requiring inhospital care and on other
types of malignancies, it cannot be excluded that the
influence of concomitant disease was underestimated.
The introduction of the 7th edition of the tumour, node,
metastases classification in 2009 provides better prog-
nostic differentiation.28 Since our study included cases
diagnosed between 2006 and 2008, some caution should
be taken when a reader generalise the findings to the
situation of today. Also, the data at hand did not allow
for assessment of performance status, forced expiratory
volume, smoking history and life style factors. Thus,
concomitant disease, poor performance status and
impaired lung function may have been both more
common and more severe in patients with low socio-
economic status, ultimately influencing choice of
treatment.
The definition of primary treatment (surgical resec-
tion, radiotherapy and chemotherapy) was based on the
registration of ‘Yes’ or ‘Unknown’. Thus, it was unclear if
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‘Unknown’ was registered as meaning no treatment or
missing information. However, it appears unlikely that
there would be a systematic misclassification of treat-
ment modality, favouring the most affluent patients. We
acknowledge that our study included no information on
second-line treatments or smoking history. Although the
income domain of the Indices of Deprivation used in the
present study is an established indicator of socioeco-
nomic status, it might not cover all aspects that
contribute to the meaning of social status. Using an area-
based deprivation index is likely to lead to an underes-
timation of social differences in survival.29 The variability
in socioeconomic status based on area characteristics will
always be smaller than that on the individual level.30 In
analyses without multiple imputation for missing values
on co-morbidity, results remained virtually unchanged
with regard to social gradients in management and
survival. Finally, the interpretation of results in some
subgroups (eg, early-stage disease) may have been
hampered by a small number of events.
Comparison with other studies
Patients diagnosed as having lung cancer are predomi-
nantly elderly smokers or ex-smokers who often have
other smoking-associated illnesses. We observed social
variations in co-morbidity burden, but there were no
differences with regard to stage at diagnosis between
socioeconomic quintiles, a finding that corroborates
with results from earlier studies.16 31 However, a recent
population-based Danish study found associations
between level of education and stage at diagnosis,32
which is in line with results from a study from USA.33 In
the present study, early-stage disease was more common
in patients with severe co-morbidity, which may reflect
that the lung malignancy was detected in the course of
medical attention for other conditions.
In the present as well as in earlier studies conducted in
Europe, choice of lung cancer management appears to
vary by social group.16 34 Corroborating results from
earlier studies,15 16 we observed social gradients in the
likelihood to undergo surgery, a finding that was inde-
pendent of age at diagnosis and co-morbidity burden.
The majority of lung cancer patients are diagnosed as
having advanced disease, where the primary goal of
treatment is to control the cancer and alleviate symp-
toms, such as cough or breathlessness. Recommended
initial treatments in advanced disease include radio-
therapy and/or chemotherapy. The 2005 Guidelines on
the management of lung cancer from the National
Institute for Health and Clinical Excellence and updated
in 2011 recommend chemotherapy in small-cell lung
cancer, given that patients are fit enough.3 In line with
our findings, socioeconomic factors have previously
been shown to be associated with chemotherapy use in
lung cancer in South East England.35
Social variations in management may be a result of
several factors. In addition to possible differences
between deprivation groups in general health status and
healthcare-seeking behaviours, there may be subtle
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differences in the doctorepatient interaction related to
socioeconomic factors. A recent Danish study found
evidence of associations between educational level and
time between referral and diagnosis,32 findings that
corroborate results from Sweden.16 Also, more affluent
patients may have better support and knowledge resulting
in increased expectations and demands on the health
provider. Furthermore, patients’ own willingness to accept
treatment and acceptance of risks associated with surgical
resection may differ by level of deprivation. Finally,
socioeconomic status has been associated with access to
cancer services, with less affluent patients having poorer
access to specialist services and treatment modalities,
referred to in the UK as a ‘postcode lottery’.36 A recent
study concluded that living in a deprived locality in
northern England reduced the likelihood of undergoing
treatment for lung cancer and suggested that central-
isation of services (thus increasing travelling distances to
specialist centres) would lead to further disadvantages for
these patients, and the same phenomenon was observed
in respect of access through a local hospital to any treat-
ment and to histological diagnosis.37
Our findings of social gradients in lung cancer survival
corroborate results from several earlier studies.8e10 16
Also, a recent report has documented persisting socio-
economic inequalities in cancer survival in England after
the introduction of the National Health Service Cancer
Plan.14 While social differences in tumour stage at time
of diagnosis have often been put forward as an expla-
nation for social inequalities in cancer survival,38 both
the present and recent results from Sweden do not
support this notion.16 One English study has even
suggested that deprived lung cancer patients are more
likely to be diagnosed as having localised disease.39
However, possible social differences in diagnostic inten-
sity, such as a higher likelihood to be examined by
Positron Emission Tomography and Computed Tomog-
raphy or CT-scan in affluent groups, could have resulted
in stage migration (‘Will Rogers phenomenon’),40 which
could inflate observed findings of social variations in
survival. We have previously observed a higher diagnostic
intensity in lung cancer patients in Sweden with high
socioeconomic status,16 which may result in more accu-
rate staging. Host factors that may contribute to social
differences in survival include co-morbidity and lifestyle
factors, both prediagnosis and postdiagnosis. In the
present study, adjustment for concomitant disease
contributed only marginally to the difference in the
survival estimates between social groups. While no
information was available on lifestyle, it cannot be
excluded that the observed inequalities in survival in
early-stage disease throughout follow-up may reflect
social differences in smoking cessation following diag-
nosis. Our findings indicate that the relative contribu-
tion of differences in treatment to social inequalities in
survival appears to be high foremost in early-stage
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Figure 2 Estimated mortality rates by socioeconomic quintile (allowing socioeconomic quintile to vary by follow-up) and the HR
between the most deprived versus the most affluent patients within 12 months of diagnosis by tumour subgroups using flexible
parametric models. (A) Early-stage non-small-cell lung cancer (NSCLC) (mortality rate). (B) Stage III disease (mortality rate). (C)
Advanced disease or small-cell lung cancer (SCLC) (mortality rate). (D) Early-stage NSCLC (HR). (E) Stage III disease (HR). (F)
Advanced disease or SCLC (HR).
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disease. This may play a particularly important role in
explaining social differences in short-term mortality
rates. Thus, increased treatment intensity among
deprived patients is likely to help reduce social
inequalities in survival.
Conclusion and policy implications
We observed socioeconomic differences in the clinical
management and in survival in patients diagnosed as
having lung cancer in the South East England between
2006 and 2008. While efforts to eliminate social differ-
ences in lung cancer incidence will take many years,
concerted action could reduce socioeconomic inequal-
ities in management and survival more quickly. Areas of
importance include efforts to guarantee equal access to
health services and monitoring of adherence to guide-
lines. The survival observed in the most affluent patient
group should set the target for what is achievable in the
short term for all lung cancer patients managed in the
same healthcare system.
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